Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation

Yao,Wanxin; Liu,Chen; Zhang,Ningyin; Zhang,Yanmei; Qian,Yong

doi:10.3892/ol.2024.14599

Atractyloside inhibits gefitinib‑resistant non‑small‑cell lung cancer cell proliferation

Authors:
- Wanxin Yao
- Chen Liu
- Ningyin Zhang
- Yanmei Zhang
- Yong Qian
View Affiliations

Affiliations: Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China, School of Laboratory Medicine and Bioengineering, Hangzhou Medical College, Hangzhou, Zhejiang 310013, P.R. China
Published online on: July 30, 2024 https://doi.org/10.3892/ol.2024.14599
Article Number: 466
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atractyloside is a traditional Chinese medicine used to treat nasal congestion, and allergic rhinitis; however, its effects on cancer are unknown. Non‑small cell lung cancer (NSCLC) is associated with high mortality rates worldwide, and relapse due to epidermal growth factor receptor mutations is a problem in clinical therapy. Therefore, novel biomarkers are required for the diagnosis and treatment of NSCLC. Brother of the regulator of imprinted sites (BORIS; also known as CTCFL) is a potential therapeutic target in NSCLC. BORIS promotes cisplatin resistance and it has been suggested that it may account for multidrug resistance. The present study examined BORIS expression in tyrosine kinase inhibitor (TKI)‑resistant NSCLC cells. Subsequently, small interfering RNA was used to knock down BORIS expression, and the effects of this knockdown were assessed on TKI‑resistant NSCLC cell viability. The present study also investigated the effect of atractyloside on the proliferation of NSCLC cells using MTT assay. The results of the present study indicated that the inhibition of BORIS or its related downstream pathways may have potential for the treatment of TKI‑resistant NSCLC. In addition, atractyloside mimicked BORIS knockdown, regulated its downstream genes and inhibited the proliferation of TKI‑resistant NSCLC cells. In conclusion, the findings of the present study supported the potential application of atractyloside in TKI‑resistant NSCLC therapy.

View Figures

View References

1	Chen LY, Hu A and Chang CJ: The degradation mechanism of toxic atractyloside in herbal medicines by decoction. Molecules. 18:2018–2028. 2013. View Article : Google Scholar : PubMed/NCBI
2	Xu J, Liu C, Shi K, Sun X, Song C, Xu K and Liu Y: Atractyloside-A ameliorates spleen deficiency diarrhea by interfering with TLR4/MyD88/NF-κB signaling activation and regulating intestinal flora homeostasis. Int Immunopharmacol. 107:1086792022. View Article : Google Scholar : PubMed/NCBI
3	Zhang P, Cheng X, Sun H, Li Y, Mei W and Zeng C: Atractyloside protect mice against liver steatosis by sctivation of autophagy via ANT-AMPK-mTORC1 Signaling Pathway. Front Pharmacol. 12:7366552021. View Article : Google Scholar : PubMed/NCBI
4	Li H, Shi X, Jiang H, Kang J, Yu M, Li Q, Yu K, Chen Z, Pan H and Chen W: CMap analysis identifies Atractyloside as a potential drug candidate for type 2 diabetes based on integration of metabolomics and transcriptomics. J Cell Mol Med. 24:7417–7426. 2020. View Article : Google Scholar : PubMed/NCBI
5	Cho J, Zhang Y, Park SY, Joseph AM, Han C, Park HJ, Kalavalapalli S, Chun SK, Morgan D, Kim JS, et al: Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance. Nat Commun. 8:144772017. View Article : Google Scholar : PubMed/NCBI
6	Ling X, Zhou Y, Li SW, Yan B and Wen L: Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells. Int J Biol Sci. 6:773–783. 2010. View Article : Google Scholar : PubMed/NCBI
7	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
8	Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 206:1074382020. View Article : Google Scholar : PubMed/NCBI
9	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
10	Aran V and Omerovic J: Current approaches in NSCLC targeting K-RAS and EGFR. Int J Mol Sci. 20:57012019. View Article : Google Scholar : PubMed/NCBI
11	Lu X, Yu L, Zhang Z, Ren X, Smaill JB and Ding K: Targeting EGFR^L858R/T790M and EGFR^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev. 38:1550–1581. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Song Y, Li C, Ren J, Fang M, Fang J and Wang X: Brother of regulator of imprinted sites inhibits cisplatin-induced DNA damage in non-small cell lung cancer. Oncol Lett. 20:2512020. View Article : Google Scholar : PubMed/NCBI
13	Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI
14	Soltanian S and Dehghani H: BORIS: A key regulator of cancer stemness. Cancer Cell Int. 18:1542018. View Article : Google Scholar : PubMed/NCBI
15	Loukinov D: Targeting CTCFL/BORIS for the immunotherapy of cancer. Cancer Immunol Immunother. 67:1955–1965. 2018. View Article : Google Scholar : PubMed/NCBI
16	Asano T, Hirohashi Y, Torigoe T, Mariya T, Horibe R, Kuroda T, Tabuchi Y, Saijo H, Yasuda K, Mizuuchi M, et al: Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy. Oncotarget. 7:11223–11237. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Fang M, Song Y, Ren J, Fang J and Wang X: Brother of regulator of imprinted sites (BORIS) suppresses apoptosis in colorectal cancer. Sci Rep. 7:407862017. View Article : Google Scholar : PubMed/NCBI
18	Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, et al: BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells. Nature. 572:676–680. 2019. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, et al: Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One. 5:e103122010. View Article : Google Scholar : PubMed/NCBI
21	Huang S, Reitze NJ, Ewing AL, McCreary S, Uihlein AH, Brower SL, Wang D, Wang T, Gabrin MJ, Keating KE, et al: Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. J Mol Diagn. 17:438–445. 2015. View Article : Google Scholar : PubMed/NCBI
22	Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
23	Fang M, Song Y, Ren J, Yuan H, Fang J, Yan D, Zhang Y and Wang X: Atractyloside mimics BORIS knockdown to induce DNA damage in colorectal cancer cells. Int J Clin Exp Pathol. 11:3286–3293. 2018.PubMed/NCBI
24	Wang R, Wang S, Li Z, Luo Y, Zhao Y, Han Q, Rong XZ, Guo YX and Liu Y: PLEKHH2 binds β-arrestin1 through its FERM domain, activates FAK/PI3K/AKT phosphorylation, and promotes the malignant phenotype of non-small cell lung cancer. Cell Death Dis. 13:8582022. View Article : Google Scholar : PubMed/NCBI
25	Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ and Bristow RG: Tumor cell kill by c-MYC depletion: Role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 70:8748–8759. 2010. View Article : Google Scholar : PubMed/NCBI
26	Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 284:122–130. 2003. View Article : Google Scholar : PubMed/NCBI
27	Jin X, Wang J, Shen H, Ran R, Xu K, Zhang W, Tong X and Feng L: Curcumin co-treatment ameliorates resistance to gefitinib in drug- resistant NCI-H1975 lung cancer cells. J Tradit Chin Med. 37:355–360. 2017. View Article : Google Scholar : PubMed/NCBI